Compare RadNet, Inc. with Similar Stocks
Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Operating profit has grown by an annual rate 53.28% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 6.12% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate 53.28% of over the last 5 years
3
The company declared very negative results in Mar'25 after flat results in Dec'24
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 5,551 Million (Small Cap)
137.00
NA
0.00%
0.33
4.44%
5.24
Revenue and Profits:
Net Sales:
523 Million
(Quarterly Results - Sep 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.77%
0%
-13.77%
6 Months
21.36%
0%
21.36%
1 Year
0.79%
0%
0.79%
2 Years
79.71%
0%
79.71%
3 Years
214.06%
0%
214.06%
4 Years
183.42%
0%
183.42%
5 Years
249.41%
0%
249.41%
RadNet, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.35%
EBIT Growth (5y)
53.28%
EBIT to Interest (avg)
1.26
Debt to EBITDA (avg)
2.58
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
0.95
Tax Ratio
54.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
98.55%
ROCE (avg)
6.37%
ROE (avg)
6.12%
Valuation key factors
Factor
Value
P/E Ratio
137
Industry P/E
Price to Book Value
4.90
EV to EBIT
57.50
EV to EBITDA
21.25
EV to Capital Employed
3.80
EV to Sales
2.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.62%
ROE (Latest)
3.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 86 Schemes (46.06%)
Foreign Institutions
Held by 136 Foreign Institutions (9.58%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
522.90
498.20
4.96%
Operating Profit (PBDIT) excl Other Income
74.60
71.40
4.48%
Interest
17.60
18.20
-3.30%
Exceptional Items
-8.80
-4.80
-83.33%
Consolidate Net Profit
13.90
23.00
-39.57%
Operating Profit Margin (Excl OI)
66.60%
71.20%
-0.46%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 4.96% vs 5.69% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -39.57% vs 177.44% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,829.70
1,616.60
13.18%
Operating Profit (PBDIT) excl Other Income
249.10
282.50
-11.82%
Interest
93.00
64.50
44.19%
Exceptional Items
-24.90
-17.10
-45.61%
Consolidate Net Profit
38.80
30.30
28.05%
Operating Profit Margin (Excl OI)
60.80%
57.50%
0.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 13.18% vs 13.04% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 28.05% vs -9.82% in Dec 2023
About RadNet, Inc. 
RadNet, Inc.
Pharmaceuticals & Biotechnology
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.
Company Coordinates 
Company Details
1510 Cotner Ave , LOS ANGELES CA : 90025-3303
Registrar Details






